Comparing two insulin resistance measures in women with PCOS taking letrozole
Compares two insulin resistance measures to predict ovulation in women with PCOS given letrozole.
Plain-language title generated from the registry record
Registry title: Comparative Study Between HOMA1-IR and HOMA2-IR in Prediction of Ovulation Outcome in Women With PCOS
Key facts
- Where
- Cairo, EgyptSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 18 to 35 with PCOS who have been trying to conceive for 1 to 4 years.
- Age
- 18 to 35 years
- Sex
- Women only
- Disease stage
- PCOS (polycystic ovarian syndrome), with infertility lasting 1 to 4 years
Main reasons for not taking part
- Other causes of infertility (tubal factor, uterine cavity abnormality, male factor)
- Endometriosis or ovarian cysts
- Diabetes mellitus, hypothalamic, pituitary or thyroid disorders, or hyperprolactinemia
- History of poor ovarian response or ovarian hyperstimulation
- Chronic, chromosomal, autoimmune or coagulation diseases, or contraindications to pregnancy
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 35 years old?
Source: NCT06793904, who can take part
Where in Egypt
- Kasr Alainy medical schoolCairo, EgyptContact: Ahmed Maged, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Cairo University
- Trial code
- NCT06793904
- Record updated
- 5 February 2025
- Original description
122 women diagnosed with PCOS seeking fertility in the fertility clinic at kasr Alainy hospital will be subjected to Homeostatic model assessment for insulin resistance 1 was calculated for all participants through the equation [glucose (mmol/L) × insulin (µU/L)]/22.5 while homeostatic model assessment for insulin resistance 2 was calculated by the HOMA2 calculator. All women will be subjected to induction of ovulation using the Aromatase inhibitor Letrozole 2.5 mg tab twice daily from the 3rd day of the cycle for 5 days . Ultrasound follow up of follicular growth will be performed till dominant follicular size reaches 18-22 mm. FSH preparations will be introduced as needed.Read full original descriptionShow less
Comparative Study Between HOMA1-IR and HOMA2-IR in Prediction of Ovulation Outcome in Women With PCOS: A Prospective Cohort Study
122 women diagnosed with PCOS seeking fertility in the fertility clinic at kasr Alainy hospital will be subjected to Homeostatic model assessment for insulin resistance 1 was calculated for all participants through the equation [glucose (mmol/L) × insulin (µU/L)]/22.5 while homeostatic model assessment for insulin resistance 2 was calculated by the HOMA2 calculator. All women will be subjected to induction of ovulation using the Aromatase inhibitor Letrozole 2.5 mg tab twice daily from the 3rd day of the cycle for 5 days . Ultrasound follow up of follicular growth will be performed till dominant follicular size reaches 18-22 mm. FSH preparations will be introduced as needed.
Inclusion: Age 18-35 years; duration of infertility 1-4 years; PCOS.
Exclusion: endocrinological abnormalities (Diabetes mellitus, hypothalamic, pituitary or thyroid disorders, or hyperprolactinemia),; women with history of poor ovarian response or ovarian hyperstimulation; women with chronic diseases, chromosomal, autoimmune or coagulation defects, abnormal leucocytic count or other inflammatory markers; women with other causes of infertility (tubal factor assessed by laparoscopy or hysterosalpingogram, uterine cavity abnormality assessed by ultrasound or hysteroscopy or male factor assessed by seme analysis),; endometriosis,; ovarian cysts,; Women with contraindications to pregnancy.